Full da­ta for Sanofi and As­traZeneca's new RSV an­ti­body raise ques­tions about just how wide­ly it will be used

A year ago, As­traZeneca and Sanofi an­nounced what the for­mer called “ground­break­ing” re­sults from a Phase III tri­al for their new ex­per­i­men­tal an­ti­body for RSV in­fec­tions, one of the lead­ing caus­es of in­fant death.

The drug, they said, sig­nif­i­cant­ly re­duced the risk of oth­er­wise healthy in­fants con­tract­ing an RSV re­quir­ing any type of med­ical at­ten­tion. This was no­table be­cause the on­ly RSV pro­phy­lac­tic cur­rent­ly on the mar­ket is on­ly used in high-risk in­fants, mean­ing the new da­ta might open up treat­ment for a new group of pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER